Atlas Trials

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Clinical trial NCT04346381 · COMPLETED

Trial details

NCT number
NCT04346381
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Solid Tumor
Start date
2020-06-05
Primary completion
2022-06-22
Enrollment
233

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.